Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 24, 2010

Drug Name Review Type Class Manufacturer
Bepreve New Drug Initial Review Ophthalmic - Allergic Conjunctivitis Ista
Vivitrol New Drug Initial Review Opioid Antagonist Alkermes
Colcrys New Drug Initial Review Anti-Gout URL
Sabril New Drug Initial Review Anticonvulsant Lundbeck
Twynsta New Drug Initial Review Antihypertensive Combination Boehringer Ingelheim
Apriso New Drug Initial Review Ulcerative Colitis Salix
Besivance New Drug Appeal Ophthalmic Fluoroquinolone Bausch & Lomb
Ranexa New Drug Appeal Anti-Anginal Giliead
Vimpat New Drug Appeal Anticonvulsant UCB
Lamictal XR New Drug Appeal Anticonvulsant GlaxoSmithKline
Ulesfia New Drug Appeal Pediculocide Shionogi
Zenpep New Drug Appeal Pancreatic Enzyme Eurand
Xibrom PDL Appeal Ophthalmic � Anti-Inflammatory Ista
Istalol PDL Appeal Ophthalmic � Glaucoma Agent Ista